Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups.

[1]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[2]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[3]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[4]  G. Raskob,et al.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies , 2013, Thrombosis Journal.

[5]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[6]  H. Heidbuchel,et al.  The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study , 2013, Circulation.

[7]  F. Lee,et al.  Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor , 2013, American Journal of Cardiovascular Drugs.

[8]  M. Monreal,et al.  Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. , 2013, The American journal of medicine.

[9]  S. Harder,et al.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations , 2013, European Journal of Clinical Pharmacology.

[10]  S. Goldhaber,et al.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. , 2013, The New England journal of medicine.

[11]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[12]  F. Scaglione.  New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists , 2013, Clinical Pharmacokinetics.

[13]  M. Franchini,et al.  New anticoagulants for treatment of venous thromboembolism. , 2012, European journal of internal medicine.

[14]  S. Kahn,et al.  Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials , 2012, BMJ : British Medical Journal.

[15]  J. Mendell,et al.  Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. , 2012 .

[16]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[17]  E. Merriman,et al.  Bleeding risk with dabigatran in the frail elderly. , 2012, The New England journal of medicine.

[18]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[19]  K. Rockwood,et al.  Frailty in primary care: a review of its conceptualization and implications for practice , 2012, BMC Medicine.

[20]  H. Büller,et al.  External and internal validity of open label or double‐blind trials in oral anticoagulation: better, worse or just different? , 2011, Journal of thrombosis and haemostasis : JTH.

[21]  F. Portaluppi,et al.  Low molecular weight heparins and glomerular filtration rate: a report to be considered. , 2011, Current vascular pharmacology.

[22]  A. Leizorovicz,et al.  No accumulation of the peak anti‐factor Xa activity of tinzaparin in elderly patients with moderate‐to‐severe renal impairment: the IRIS substudy , 2011, Journal of thrombosis and haemostasis : JTH.

[23]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[24]  Candice L. Garwood,et al.  Effect of Chronic Kidney Disease on Warfarin Management in a Pharmacist-Managed Anticoagulation Clinic , 2011, Journal of managed care pharmacy : JMCP.

[25]  A. Leizorovicz,et al.  Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS). , 2011, Thrombosis research.

[26]  J. Nunnelee.  Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510. , 2011, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.

[27]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[28]  M. Samama.  Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment , 2011, Drugs & aging.

[29]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[30]  M. Righini,et al.  Anticoagulation in the Elderly , 2010, Pharmaceuticals.

[31]  F. Rosendaal,et al.  Venous thrombosis in the elderly: incidence, risk factors and risk groups , 2010, Journal of thrombosis and haemostasis : JTH.

[32]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[33]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[34]  N. Limdi,et al.  Kidney function influences warfarin responsiveness and hemorrhagic complications. , 2009, Journal of the American Society of Nephrology : JASN.

[35]  A. Verma,et al.  The Direct Factor Xa Inhibitor Rivaroxaban , 2022 .

[36]  Haiying Liu,et al.  Lessons learned from the contamination of heparin. , 2009, Natural product reports.

[37]  D. Rakheja,et al.  The aging kidney. , 2008, Kidney international.

[38]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[39]  A. Dreisbach,et al.  The effect of chronic renal failure on drug metabolism and transport , 2008 .

[40]  C. Esmon,et al.  Venous thrombosis in the elderly: more questions than answers. , 2007, Blood.

[41]  R. Powell,et al.  Heparin induced thrombocytopenia: diagnosis and management update , 2007, Postgraduate Medical Journal.

[42]  M. Crowther,et al.  Low molecular weight heparin and bleeding in patients with chronic renal failure. , 2007, Current opinion in pulmonary medicine.

[43]  S. Kahn,et al.  Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice , 2007, Journal of thrombosis and haemostasis : JTH.

[44]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. , 2007, Haematologica.

[45]  A. Maestre,et al.  Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. , 2006, The American journal of medicine.

[46]  M. Pirmohamed.  Warfarin: almost 60 years old and still causing problems. , 2006, British journal of clinical pharmacology.

[47]  R. Levine,et al.  How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? , 2006, Chest.

[48]  B. Ickx,et al.  Perioperative management of patients receiving vitamin K antagonists , 2006, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[49]  F. Dentali,et al.  Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency , 2006, Annals of Internal Medicine.

[50]  E. Hylek,et al.  Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. , 2005, Chest.

[51]  F. García-Bragado,et al.  The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE) , 2005, Journal of thrombosis and haemostasis : JTH.

[52]  M. Bullano,et al.  Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. , 2004, Clinical therapeutics.

[53]  Stephen H. D. Jackson,et al.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. , 2003, British journal of clinical pharmacology.

[54]  E. Oger.  Incidence of Venous Thromboembolism: A Community-based Study in Western France , 2000, Thrombosis and Haemostasis.

[55]  W M O'Fallon,et al.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.

[56]  G. Raskob,et al.  Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. , 1997, Archives of internal medicine.

[57]  G. Raskob,et al.  Aging and heparin-related bleeding. , 1996, Archives of internal medicine.

[58]  J. H. Nicholson,et al.  Coumadin (warfarin) sodium; a new anticoagulant. , 1956, The New England journal of medicine.

[59]  M. Monreal,et al.  Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). , 2006, Haematologica.

[60]  I. Gouin-Thibault,et al.  Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose , 2005, Drug safety.